linjc16/ctgov huggingface dataset:
Mortality Analysis of ST Elevation Myocardial Infarction (STEMI) Patients in Belgium

Study Overview
=================
Brief Summary
-----------------
The purpose of this observational study is to assess predictors of in-hospital mortality in patients with acute myocardial infarction admitted to Belgian hospitals.

Official Title
-----------------
Prospective Observational Study to Assess Predictors of in Hospital Mortality in STEMI Patients Admitted in Belgian Hospitals

Conditions
-----------------
Acute Myocardial Infarction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: clinical diagnosis of acute myocardial infarction with ST elevation or left bundle branch blok pattern on ECG Exclusion Criteria: acute myocardial infarction as an acute complication of coronary intervention
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| all cause mortality |  | one month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
acute coronary syndrome, myocardial infarction, predictors of mortality, reperfusion therapy
The Infected Bone Nonunion and Soft Tissue Defect of Long Bone Treated Simultaneously With Ilizarov Technique

Study Overview
=================
Brief Summary
-----------------
In this retrospective study, the investigators evaluated the clinical and functional results of infected nonunion of the long bone with soft-tissue defects treated simultaneously with Ilizarov technique combining open dressing change in 22 patients. The investigators wanted to find out whether that the internal bone transport with external fixator combining open dressing change is a valuable method to treatment for those patients with infected bone nonunion and poor condition of the soft tissue such as sinus, skin defect.

Detailed Description
-----------------
From January 2002 to now, totally 22 patients (18 males, 4 females) were underwent internal bone transport for infected nonunion in the long bone with soft-tissue defects. The mean age of the patients was 36.5 years (range, 19 to 57). The infected nonunion occurred on the femur in 1 patients, the tibia in 21 patients. The hybrid mono-lateral limb reconstruction external fixator was used, combined with bone transport. The results were evaluated by the classification of the Association for the Study and Application of the Method of Ilizarov (ASAMI) which divided into bone and functional categories

Official Title
-----------------
The Infected Bone Nonunion and Soft Tissue Defect of Long Bone Treated Simultaneously With Ilizarov Technique

Conditions
-----------------
Trauma, Orthopedic Surgery Complications

Intervention / Treatment
-----------------
* Device: Use it to treatment bone nonunion (Ilzarov)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with infected nonunion of long bone with soft tissue defects or sinus, without systemic illness that could affect their immunologic status (e.g., AIDS, diabetes mellitus, liver cirrhosis). Exclusion Criteria: Patient noncooperation and an age of less than 18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ilzarov<br> | Device: Use it to treatment bone nonunion (Ilzarov)<br>* Detect the variation of limb lengthening<br>* Other names: Trauma;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Achive wounds close and bone union |  | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
infected, Ilizarov
Evaluation and Natural History of Children With Cancer and AIDS

Study Overview
=================
Brief Summary
-----------------
Patients enrolled in this study will not receive investigational therapy. Any treatments rendered will be standard and based on appropriate medical care. Should a patient become eligible for an experimental therapy protocol, the normal process of enrollment and informed consent will be followed.

Detailed Description
-----------------
This protocol will enable the Pediatric Branch to follow selected children with cancer or HIV infection who are not immediately eligible for protocol enrollment but who are likely, within the next year, to become candidates for protocol entry. It will also enable the Pediatric Branch to follow children who present with either clinical findings that constitute important educational experiences for the NCI trainees or who have unique or unusual medical problems that are likely to benefit from the research expertise of the NCI.

Official Title
-----------------
Evaluation and Natural History of Children With Cancer and AIDS

Conditions
-----------------
Acquired Immunodeficiency Syndrome, Cancer, HIV Infections, Leukemia, Lymphoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Children with cancer (or a precancer syndrome) or HIV infection, between the age(s) of 3 months to 30 years, who are evaluated by the Pediatric Branch and are found to be not immediately eligible for an ongoing protocol but are likely to become a candidate for a future protocol. Children with cancer (or a precancer syndrome) or HIV infection, who present with disease manifestations of special interest to Pediatric Branch investigators, because they are likely to shed light on disease. Patients who, when evaluated by the Branch, are determined to likely never become eligible for a Pediatric Branch protocol are not eligible for this protocol. No patients younger than 3 months of age or older than 30 years of age are eligible for this protocol.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
AIDS, Children, Human Immunodeficiency Virus
Lesion Contiguity in Very High Power-short Duration Ablation

Study Overview
=================
Brief Summary
-----------------
This observational trial investigates the effect of very high power-short duration radiofrequency ablation on lesion contiguity as assessed by late gadolinium enhancement cardiovascular magnetic resonance (LGE-CMR). Patients with paroxysmal or early persistent atrial fibrillation (AF) scheduled for pulmonary vein isolation (PVI) undergo point-by-point ablation using the QDOT micro catheter applying Qmode+ (90W over 4 seconds). All patients receive an LGE-CMR 3 months after the procedure for ablation lesion assessment. Contiguity of LGE-CMR-detected ablation lesions will be compared with a matched control group of patients that have undergone PVI accomplished by ablation index-guided ablation with 40 W following the CLOSE protocol.

Official Title
-----------------
Effect of Very High Power-short Duration Ablation on Lesion Contiguity in Pulmonary Vein Isolation as Assessed by Late Gadolinium Enhancement Cardiovascular Magnetic Resonance

Conditions
-----------------
Atrial Fibrillation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: paroxysmal or early persistent (max. 3 months) atrial fibrillation scheduled for PVI-only catheter ablation Exclusion Criteria: long-standing persistent atrial fibrillation previous left atrial ablation claustrophobia preventing CMR sever renal insufficiency (GFR >30 ml/min) gadolinium contrast allergy presence of implantable devices not compatible with magnetic resonance pregnancy and lactation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Very high power-short duration ablation<br>PVI performed by point-by-point very high power-short duration radiofrequency ablation (QDOT-micro catheter, Biosense Webster; Qmode+; 90 W; 4 sec; target intertag distances: posterior wall 4 mm, proximity of the esophagus 5 mm, all other 3 mm) | |
| Matched control group conventional ablation<br>PVI performed by conventional point-by-point radiofrequency ablation (40 W; ablation index-guided: posterior wall 350, other 450; target intertag distance 3.0 - 5.0 mm) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ablation lesion contiguity as assessed by LGE-CMR | Proportion of the circumferential ablation line covered by LGE (%) | LGE-CMR at 3 months post-ablation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Catheter ablation
Investigation of Genetic Disease Marker Associated With Spontaneous Haemorrhagic Stroke Complicating Severe Pre-eclampsia in Pregnancy

Study Overview
=================
Brief Summary
-----------------
To search for a genetic marker of hemorrhagic stroke complicating severe eclampsia, a single nucleotide polymorphism (SNP) analysis of DNA obtained from the peripheral blood of patients with hemorrhagic stroke and normal control will be performed.

Detailed Description
-----------------
Detailed Description: Unrelated Korean subjects who have Spontaneous hemorrhagic stroke complicating severe eclampsia in pregnancy were recruited in the current study. Genotyping for various SNP associated due to the linkage disequilibrium patterns is to be performed. Genotypes would be statistically compared between patients with hemorrhagic stroke and normal control subjects free of hemorrhagic stroke

Official Title
-----------------
Preventive and Personalized Medicine (2021-2023)

Conditions
-----------------
Hemorrhagic Stroke, Eclampsia

Intervention / Treatment
-----------------
* Genetic: SNP analysis of the DNA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: -patients with hemorrhagic stroke complicating severe eclampsia in pregnancy Exclusion Criteria: patients without hemorrhagic stroke complicating severe eclampsia in pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental group:<br>patients with hemorrhagic stroke complicating severe pre-eclampsia in pregnancy | Genetic: SNP analysis of the DNA<br>* SNP analysis of the DNA obtained from peripheral blood sample<br>|
| Control group<br>patients without hemorrhagic stroke complicating severe pre-eclampsia in pregnancy | Genetic: SNP analysis of the DNA<br>* SNP analysis of the DNA obtained from peripheral blood sample<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| genotyping for the SNP associated with hemorrhagic stroke complicating severe eclampsia in pregnancy |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
SNP
Effect of Caffeine on Fetal Growth

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether caffeine has any effect on birth weight.

Official Title
-----------------
The Importance of Caffeine in Fetal Growth

Conditions
-----------------
Birth Weight

Intervention / Treatment
-----------------
* Drug: Nescafé Gold Blend (exposed)
* Drug: Nescafé Decaffeinated (controls)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pregnant Consumption of at least 3 cups of coffee/day at recruitment Exclusion Criteria: Gestational age more than 20 weeks at recruitment Chronic kidney disease Epilepsy Insulin dependent diabetes Metabolic disorder Previous low birth weight delivery Previous preterm delivery

Ages Eligible for Study
-----------------
Minimum Age: 0 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Nescafé Gold Blend (exposed)|nan|
|Drug: Nescafé Decaffeinated (controls)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| birth weight |  |  | 
| gestational age |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Caffeine, Coffee, Randomized, Birth weight
Risk Factors of the Revisit of the Adult Heart Failure Patients in Emergency Department Siriraj Hospital

Study Overview
=================
Brief Summary
-----------------
To identify the risk factors of the revisit of the adult HF patients in emergency department.

Detailed Description
-----------------
Because heart failure (HF) is the leading cause of hospitalization and readmission in many hospitals worldwide. Identifying the risk factors of these HF patients in emergency department is the important reason for the proper management of the HF patients in the future. And can reduce number of hospitalization and readmission in our hospital.

Official Title
-----------------
Risk Factors of the Revisit of the Adult Heart Failure Patients in Emergency Department in Siriraj Hospital: The One Year Period.

Conditions
-----------------
Congestive Heart Failure, Renal Insufficiency

Intervention / Treatment
-----------------
* Other: Patient charts reviewing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients age from 18 years old Patients who were diagnosed HF by the Framingham's criteria10 Patients who were discharged home from emergency department Exclusion Criteria: Patients age less than 18 years old Patients who not met Framingham's criteria, needed hospital admission, were referred to other hospital, and death

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Revisit<br>HF patients who revisit the emergency department before the next appointment date. | Other: Patient charts reviewing<br>* Reviewing chart and identifying risk factors<br>|
| Non-revisit<br>HF patients who follow up on the appointment date. | Other: Patient charts reviewing<br>* Reviewing chart and identifying risk factors<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of HF patients who were revisited emergency department before the appointment date. | All HF-peatient charts were reviewed and divided in revisit group and non revisit group. | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Characteristics of the patients in revisit group | The Characteristics of the patients in both groups such as underlying diseases, ejection fraction, and time for treating in emergency department. The results were compared to find the relation between both groups. | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Heart failure, Revisit, Emergency room
Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis

Study Overview
=================
Brief Summary
-----------------
This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-147 in participants with apolipoprotein L1 (APOL1)-mediated focal segmental glomerulosclerosis (FSGS).

Official Title
-----------------
A Phase 2a, Open-label, Single-arm, 2-Part Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis

Conditions
-----------------
Glomerulosclerosis, Focal Segmental

Intervention / Treatment
-----------------
* Drug: VX-147


Participation Criteria
=================
Eligibility Criteria
-----------------
Key Inclusion Criteria: APOL1 genotype of G1/G1, G2/G2, or G1/G2 FSGS diagnosed by kidney biopsy Key Exclusion Criteria: Evidence of non-APOL1-mediated FSGS Participants with known sickle cell disease Solid organ or Bone marrow transplant Other protocol defined Inclusion/Exclusion criteria may apply.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: VX-147<br>All participants received VX-147 at a dosage of 15 mg once daily (qd) for 2 weeks and VX-147 at a dosage of 45 mg qd for 11 weeks. Part A was enrolled in 2 cohorts: Cohort 1 and Cohort 2. Cohort 1 included participants with urine protein to creatinine ratio (UPCR) approximately greater than or equal to (≥) 3 g/g (± 10%) and less than (<) 10 g/g and estimated glomerular filtration rate (eGFR) approximately ≥30 mL/min/1.73 m2 (± 10%). Cohort 2 included participants with UPCR approximately ≥0.8 g/g (± 10%) and <2.7 g/g and eGFR approximately ≥30 mL/min/1.73 m2. | Drug: VX-147<br>* Tablets for oral administration.<br>* Other names: IXP;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent Change From Baseline in UPCR |  | From Baseline up to Week 13 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) |  | From Baseline up to Week 17 | 
| Maximum Observed Concentration (Cmax) of VX-147 |  | Pre-dose and at 0.25, 0.5, 1, 2, 4, and 12 hours post-dose on Day 1 and Week 5 | 
| Observed Pre-dose Concentration (Ctrough) of VX-147 |  | Pre-dose on Day 8, 15, Week 3, 5, 9 and 13 | 
| Area Under the Concentration Time-curve From 0 to 24 Hours (AUC0-24hr) of VX-147 |  | Pre-dose and at 0.25, 0.5, 1, 2, 4, 12 and 24 hours Post-dose on Week 5 |
Open Label Continuation Study in Moderate to Severe Psoriasis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate long term safety, efficacy and tolerability of ABT-874 in adults with moderate to severe psoriasis.

Official Title
-----------------
A Phase 3, Multi-center, Open-label Continuation Study in Moderate to Severe Plaque Psoriasis in Subjects Who Completed a Preceding Psoriasis Study With ABT-874

Conditions
-----------------
Moderate to Severe Plaque Psoriasis

Intervention / Treatment
-----------------
* Drug: ABT-874


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Having participated in a preceding ABT-874 clinical trial for ABT-874 Subject has a clinical diagnosis of moderate to severe plaque psoriasis Exclusion Criteria: Subjects who prematurely discontinued in any preceding psoriasis study with ABT-874 other than protocol-required discontinuation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Drug: ABT-874<br>* 100mg ABT-874 administered SQ every 4 wks for approximately 204 weeks<br>* Other names: briakinumab;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of subjects achieving PGA clear (0) or minimal (1) scores by visit. |  | Visit (12 weeks) | 
| Proportion of subjects achieving a > PASI 50 clinical response that is defined as a reduction on PASI scores by at least 50% relative to Baseline, by visit. |  | Visit (12 weeks) | 
| Proportion of subjects achieving a > PASI 75 clinical response that is defined as a reduction on PASI scores by at least 50% relative to Baseline, by visit. |  | Visit (12 weeks) | 
| AEs, serious adverse events (SAEs), laboratory data, ADA and vital signs will be assessed throughout the study |  | Visit (12 weeks) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Open label